Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Acronyms BRAVE
- Sponsors Takeda
Most Recent Events
- 27 Jan 2025 Planned End Date changed from 1 Jan 2025 to 19 Jun 2026.
- 27 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 19 Jun 2026.
- 27 Jan 2025 Status changed from recruiting to active, no longer recruiting.